Page 1 | Search Results | Blood | American Society of Hematology

1-19 of 19

Sort by

Sort Order Select

Journal Articles

NKTR-255 Vs Placebo to Enhance Complete Responses and Durability Following CD19-Directed CAR-T Therapy in Patients with Relapsed/ Refractory (R/R) Large B-Cell Lymphoma (LBCL)

Sairah Ahmed, John F. DiPersio, James H Essell, Catherine S. Diefenbach, Miguel Angel Perales, Cristina Castilla-Llorente, Saurabh Dahiya, Sohail Chaudhry, Heng Xu, Yi Liu, Christie Fanton, Zachary Lee, Mario Q. Marcondes, Mary Tagliaferri, Jonathan Zalevsky, David B. Miklos, Cameron J. Turtle, Joseph P. McGuirk

Blood (2024) 144 (Supplement 1): 2068.

https://doi.org/10.1182/blood-2024-203576

Published: 2024

Journal Articles

Safety, Tolerability, PK/PD and Preliminary Efficacy of NKTR-255, a Novel IL-15 Receptor Agonist, in Patients with Relapsed/Refractory Hematologic Malignancies

Blood (2022) 140 (Supplement 1): 10357–10359.

https://doi.org/10.1182/blood-2022-162539

Published: 2022

Journal Articles

A Phase Ib Open-Label Study Evaluating the Safety and Efficacy of NKTR-255 in Combination with CD19-Directed CAR-T Cell Therapy in Patients with Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL)

Alexandre Vinaud Hirayama, Cassie Chou, David G. Maloney, Mario Q. Marcondes, Cameron J. Turtle

Blood (2022) 140 (Supplement 1): 12747–12748.

https://doi.org/10.1182/blood-2022-160191

Published: 2022

Journal Articles

A Phase 2/3, Randomized, Double Blind, Placebo-Controlled, Multicenter Study of NKTR-255 Vs Placebo Following CD-19 Directed CAR-T Therapy in Patients with Relapsed/Refractory Large B-Cell Lymphoma

Miguel-Angel Perales, Sairah Ahmed, Saurabh Dahiya, Peter A. Riedell, Joseph P. McGuirk, Olalekan O. Oluwole, Sohail A. Chaudhry, Zachary Lee, Stanley Dai, Neha Dixit, Christie Fanton, Mario Q. Marcondes, Jonathan Zalevsky, Mary A. Tagliaferri, Cameron J. Turtle

Blood (2022) 140 (Supplement 1): 7488–7490.

https://doi.org/10.1182/blood-2022-162511

Published: 2022

Journal Articles

Pharmacodynamic Analysis of CAR-T Cell Persistence in Patients with Hematologic Malignancies Treated with NKTR-255, an IL-15 Receptor Agonist That Enhances CD8 + T-Cells: Preliminary Results from a Phase 1 Study

Cameron J. Turtle, Elizabeth Budde, Krina K. Patel, Miguel-Angel Perales, Andrew J. Cowan, Hayder Saeed, Julio C. Chavez, Alexandre V. Hirayama, Delaney R. Kirchmeier, Murali Janakiram, Kai Wu, Lawrence Fong, Zachary Lee, Neha Dixit, Xiaoli Wang, Kazuharu Kai, Mario Q. Marcondes, Jonathan Zalevsky, Nina Shah

Blood (2021) 138 (Supplement 1): 2815.

https://doi.org/10.1182/blood-2021-147350

Published: 2021

Journal Articles

Safety, Tolerability, PK/PD and Preliminary Efficacy of NKTR-255, a Novel IL-15 Receptor Agonist, in Patients with Relapsed/Refractory Hematologic Malignancies

Blood (2021) 138 (Supplement 1): 3134.

https://doi.org/10.1182/blood-2021-147758

Published: 2021

Journal Articles

Optimizing Ex-Vivo Expanded NK Cell- Mediated Antibody-Dependent Cellular Cytotoxicity (ADCC) Combined with NKTR-255 in Chronic Lymphocytic Leukemia (CLL), Follicular Lymphoma (FL), and Burkitt Lymphoma (BL)

Yaya Chu, PhD, Susiyan Jiang, MS, Jian Jiang, MD, Meijuan Tian, PhD, Dean Anthony Lee, MD PhD, Loui Madakamutil, Mario Q. Marcondes, MDPhD, Christian Klein, PhD, Mitchell S Cairo, MD

Blood (2020) 136 (Supplement 1): 23–24.

https://doi.org/10.1182/blood-2020-139822

Published: 2020

Journal Articles

Combination of NKTR-255, a Polymer Conjugated Human IL-15, with CD19 CAR T Cell Immunotherapy in a Preclinical Lymphoma Model

Cassie Chou, MD PhD, Simon Fraessle, Rachel Steinmetz, BSc, Reed M. Hawkins, BS, Tinh-Doan Phi, BS, Dirk Busch, Takahiro Miyazaki, Mario Q. Marcondes, MD PhD, Stanley R. Riddell, MD, Cameron J. Turtle, MBBS, PhD

Blood (2019) 134 (Supplement_1): 2866.

https://doi.org/10.1182/blood-2019-125960

Published: 2019

Journal Articles

A Phase 1, Open-Label, Multi-Center, Dose Escalation and Dose Expansion Study of NKTR-255 As a Single Agent in Relapsed or Refractory Hematologic Malignancies and in Combination with Daratumumab As a Salvage Regimen for Multiple Myeloma

Nina D. Shah, MD, Cameron J. Turtle, MBBS, PhD, Andrew J. Cowan, MD, Julio C. Chavez, MD, Lihua E Budde, MD PhD, Mario Q. Marcondes, MD PhD, Zachary Lee, PharmD, Wei Lin, MD, Jonathan Zalevsky, Mary Tagliaferri, MD, Krina K. Patel, MDMSc

Blood (2019) 134 (Supplement_1): 4459.

https://doi.org/10.1182/blood-2019-122494

Published: 2019

Journal Articles

NKTR-255, a Polymer-Conjugated IL-15 Enhances Antibody-Dependent Cellular Cytotoxicity Mediated By NK Cells in a B Cell Lymphoma Model

Takahiro Miyazaki, Saul Kivimäe, Marlene Hennessy, Rhoneil Pena, Phi Quach, Andrew Moffet, Wildaliz Nieves, Ping Zhang, Mario Q. Marcondes, MD PhD, Loui Madakamutil, Jonathan Zalevsky

Blood (2019) 134 (Supplement_1): 5302.

https://doi.org/10.1182/blood-2019-127771

Published: 2019

Journal Articles

Pharmacokinetic and Pharmacodynamic Study of NKTR-255, a Polymer-Conjugated Human IL-15, in Cynomolgus Monkey

Takahiro Miyazaki, Peiwen Kuo, Mekhala Maiti, Palakshi Obalapur, Murali Addepalli, Werner Rubas, Paul Sims, Ping Zhang, Mario Q. Marcondes, MD PhD, Loui Madakamutil, Jonathan Zalevsky

Blood (2018) 132 (Supplement 1): 2952.

https://doi.org/10.1182/blood-2018-99-115638

Published: 2018

Journal Articles

Interim Results of a Phase 1b/2 Study of Entospletinib (GS-9973) Monotherapy and in Combination with Chemotherapy in Patients with Acute Myeloid Leukemia

Alison R. Walker, MD MPH, Bhavana Bhatnagar, DO, A. Mario Q. Marcondes, MD, Julie DiPaolo, PhD, Sumithra Vasu, MBBS, Alice S. Mims, MD MSCR, Rebecca B. Klisovic, MD, Katherine J. Walsh, MD, Renee Canning, RN, Gregory K. Behbehani, MD PhD, Ramiro Garzon, MD, James S. Blachly, MD, Amy J. Johnson, PhD, Esteban Abella-Dominicis, John C. Byrd, MD, William Blum, MD

Blood (2016) 128 (22): 2831.

https://doi.org/10.1182/blood.V128.22.2831.2831

Published: 2016

Journal Articles

Myelodysplastic Syndrome Marrow Stroma Shows Widespread Aberrant Hypermethylation That Is Abrogated By Treatment with Dnmt Inhibitors

Tushar D Bhagat, PhD, Matthias Bartenstein, MD, Yiting Yu, PhD, A. Mario Q. Marcondes, MD PhD, Britta Will, PhD, Orsolya Giricz, PhD, Davendra P. Sohal, MD MPH, Ioannis Mantzaris, MD, Amittha Wickrema, PhD, Christine Mcmahon, MD, Yeung Cecilia, MD, John Greally, MB, PhD, Siddhartha Mukherjee, MD PhD, Ulrich Steidl, MD PhD, H. Joachim Deeg, MD, Amit Verma, MD

Blood (2014) 124 (21): 4379.

https://doi.org/10.1182/blood.V124.21.4379.4379

Published: 2014

Journal Articles

Alpha 1 Anti-Trypsin (AAT) Offers Potent Therapy for Steroid Resistant Gut Gvhd: Interim Results of a Phase I/II Clinical Study

A. Mario Q. Marcondes, MD PhD, Mohamed L. Sorror, MD, Ekapun Karoopongse, MD, Terry Furlong, NP, Marina Lesnikova, PhD, Sabina Janciauskiene, MD, Charles A. Dinarello, MD, H. Joachim Deeg, MD

Blood (2014) 124 (21): 3927.

https://doi.org/10.1182/blood.V124.21.3927.3927

Published: 2014

Journal Articles

The Jumanjii Histone Demethylase KDM2B controls EZH2 Expression In Myelodysplastic Syndromes (MDS) Via Mir Let-7b (let7b), a Pathway That Is Bypassed By The Histone Methylation Inhibitor DZNep

Ekapun Karoopongse, MD, John Byon, MD, PhD, Cecilia Yeung, MD, H. Joachim Deeg, MD, A. Mario Q. Marcondes, MD, PhD

Blood (2013) 122 (21): 1543.

https://doi.org/10.1182/blood.V122.21.1543.1543

Published: 2013

Journal Articles

Donor Treatment with α1 Anti-Trypsin (AAT) Mitigates Gvhd and Increases Survival While Sparing GVL Effects

A. Mario Q. Marcondes, MD, PhD, Ekapun Karoopongse, MD, Marina Lesnikova, PhD, Sabina Janciauskiene, MD, Charles A. Dinarello, M.D., H. Joachim Deeg, MD

Blood (2012) 120 (21): 1889.

https://doi.org/10.1182/blood.V120.21.1889.1889

Published: 2012

Journal Articles

α1 Anti-Trypsin (AAT) Mitigates Hematopoietic Injury and Enhances Bone Marrow Recovery After Total Body Irradiation (TBI)

Ekapun Karoopongse, MD, Sabina Janciauskiene, MD, Charles A. Dinarello, M.D., H. Joachim Deeg, A. Mario Q. Marcondes, MD, PhD

Blood (2012) 120 (21): 4142.

https://doi.org/10.1182/blood.V120.21.4142.4142

Published: 2012

Journal Articles

Interleukin-32, α1 Anti-Trypsin (AAT-1) and Graft-Versus-Host-Disease

A. Mario Q. Marcondes, MD, PhD, Laura Tabellini, John A. Hansen, MD, Charles A. Dinarello, MD, H. Joachim Deeg, MD

Blood (2010) 116 (21): 522.

https://doi.org/10.1182/blood.V116.21.522.522

Published: 2010

Journal Articles

Identification of DJ-1/Park-7 as a Determinant of Tnfα-Induced and Stroma-Dependent Apoptosis in Leukemia Using Mass Spectometry and Phosphopetide Analysis.

A. Mario Q. Marcondes, MD, Li Xiang, Brian P Milless, H. Joachim Deeg

Blood (2008) 112 (11): 1796.

https://doi.org/10.1182/blood.V112.11.1796.1796

Published: 2008

NARROW

NKTR-255 Vs Placebo to Enhance Complete Responses and Durability Following CD19-Directed CAR-T Therapy in Patients with Relapsed/ Refractory (R/R) Large B-Cell Lymphoma (LBCL)

Safety, Tolerability, PK/PD and Preliminary Efficacy of NKTR-255, a Novel IL-15 Receptor Agonist, in Patients with Relapsed/Refractory Hematologic Malignancies

A Phase Ib Open-Label Study Evaluating the Safety and Efficacy of NKTR-255 in Combination with CD19-Directed CAR-T Cell Therapy in Patients with Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL)

A Phase 2/3, Randomized, Double Blind, Placebo-Controlled, Multicenter Study of NKTR-255 Vs Placebo Following CD-19 Directed CAR-T Therapy in Patients with Relapsed/Refractory Large B-Cell Lymphoma

Pharmacodynamic Analysis of CAR-T Cell Persistence in Patients with Hematologic Malignancies Treated with NKTR-255, an IL-15 Receptor Agonist That Enhances CD8 + T-Cells: Preliminary Results from a Phase 1 Study

Safety, Tolerability, PK/PD and Preliminary Efficacy of NKTR-255, a Novel IL-15 Receptor Agonist, in Patients with Relapsed/Refractory Hematologic Malignancies

Optimizing Ex-Vivo Expanded NK Cell- Mediated Antibody-Dependent Cellular Cytotoxicity (ADCC) Combined with NKTR-255 in Chronic Lymphocytic Leukemia (CLL), Follicular Lymphoma (FL), and Burkitt Lymphoma (BL)

Combination of NKTR-255, a Polymer Conjugated Human IL-15, with CD19 CAR T Cell Immunotherapy in a Preclinical Lymphoma Model

A Phase 1, Open-Label, Multi-Center, Dose Escalation and Dose Expansion Study of NKTR-255 As a Single Agent in Relapsed or Refractory Hematologic Malignancies and in Combination with Daratumumab As a Salvage Regimen for Multiple Myeloma

NKTR-255, a Polymer-Conjugated IL-15 Enhances Antibody-Dependent Cellular Cytotoxicity Mediated By NK Cells in a B Cell Lymphoma Model

Pharmacokinetic and Pharmacodynamic Study of NKTR-255, a Polymer-Conjugated Human IL-15, in Cynomolgus Monkey

Interim Results of a Phase 1b/2 Study of Entospletinib (GS-9973) Monotherapy and in Combination with Chemotherapy in Patients with Acute Myeloid Leukemia

Myelodysplastic Syndrome Marrow Stroma Shows Widespread Aberrant Hypermethylation That Is Abrogated By Treatment with Dnmt Inhibitors

Alpha 1 Anti-Trypsin (AAT) Offers Potent Therapy for Steroid Resistant Gut Gvhd: Interim Results of a Phase I/II Clinical Study

The Jumanjii Histone Demethylase KDM2B controls EZH2 Expression In Myelodysplastic Syndromes (MDS) Via Mir Let-7b (let7b), a Pathway That Is Bypassed By The Histone Methylation Inhibitor DZNep

Donor Treatment with α1 Anti-Trypsin (AAT) Mitigates Gvhd and Increases Survival While Sparing GVL Effects

α1 Anti-Trypsin (AAT) Mitigates Hematopoietic Injury and Enhances Bone Marrow Recovery After Total Body Irradiation (TBI)

Interleukin-32, α1 Anti-Trypsin (AAT-1) and Graft-Versus-Host-Disease

Identification of DJ-1/Park-7 as a Determinant of Tnfα-Induced and Stroma-Dependent Apoptosis in Leukemia Using Mass Spectometry and Phosphopetide Analysis.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only